The GIPSS is based exclusively on genetic markers (mutations and karyotype), whereas the MIPSS70 includes mutations and clinical risk factors.
MIPSS70+ version 2.0 is an adaptation of MIPSS70 that includes a three-tiered cytogenetic risk stratification and use of hemoglobin thresholds that are adjusted for sex and severity; this is the preferred model in the presence of cytogenetic information.
Both MIPSS70 and MIPSS70+ version 2.0 require an online score calculator, whereas GIPPS offers a lower-complexity prognostic tool that reliably identifies candidates for allo-HCT (GIPSS high-risk disease) or long-term observation with little or no therapeutic intervention (GIPSS low-risk disease).
Learn more about prognostic scoring systems for patients with PMF.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Emmanuel C. Besa. Fast Five Quiz: Prognosis of Primary Myelofibrosis - Medscape - Jul 16, 2020.